National Institutes of Health: Leukemia, Promyelocytic, Acute trials
The registry lists 22 Leukemia, Promyelocytic, Acute studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 16Phase 2 7Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingNCT02390752Phase 1
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT01445080Phase 1/2Results posted
- Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01253070Phase 2Results posted
- Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00313586Phase 2Results posted
- Vorinostat in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00305773Phase 2Results posted
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
- Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
- Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
- Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
- Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00062075Phase 2
- Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT00042796Phase 1
- Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic LeukemiaWithdrawnNCT00030355Phase 1/2
- BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
- PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
- Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00003934Phase 3